Shares of Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) were down 6.7% during mid-day trading on Wednesday . The company traded as low as $1.25 and last traded at $1.26. Approximately 2,182,873 shares traded hands during mid-day trading, an increase of 404% from the average daily volume of 433,153 shares. The stock had previously closed at $1.35.
A number of analysts have recently weighed in on OHRP shares. Roth Capital started coverage on shares of Ohr Pharmaceuticals in a report on Monday, November 27th. They set a “buy” rating and a $7.00 price target for the company. Zacks Investment Research raised shares of Ohr Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday, October 25th. ValuEngine raised shares of Ohr Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Finally, HC Wainwright set a $10.00 price target on shares of Ohr Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 16th.
Institutional investors have recently modified their holdings of the company. Garrison Bradford & Associates Inc. lifted its stake in Ohr Pharmaceuticals by 482.4% in the 3rd quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock valued at $358,000 after purchasing an additional 412,000 shares during the last quarter. Wedbush Securities Inc. bought a new position in Ohr Pharmaceuticals in the 3rd quarter valued at approximately $311,000. Vanguard Group Inc. lifted its stake in Ohr Pharmaceuticals by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock valued at $520,000 after purchasing an additional 5,481 shares during the last quarter. Cannell Peter B & Co. Inc. bought a new position in Ohr Pharmaceuticals in the 2nd quarter valued at approximately $187,000. Finally, Renaissance Technologies LLC lifted its stake in Ohr Pharmaceuticals by 242.3% in the 1st quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 162,600 shares during the last quarter. 8.40% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.com-unik.info/2017/12/06/ohr-pharmaceuticals-ohrp-shares-down-6-7.html.
About Ohr Pharmaceuticals
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
What are top analysts saying about Ohr Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ohr Pharmaceuticals Inc. and related companies.